<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797758</url>
  </required_header>
  <id_info>
    <org_study_id>P 060206</org_study_id>
    <nct_id>NCT00797758</nct_id>
  </id_info>
  <brief_title>Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia</brief_title>
  <acronym>MINICORD</acronym>
  <official_title>Assessment of Reduction of Cord Blood Transplantation Toxicity by Using Reduced Intensity Conditioning in Patients With Acute Myeloid Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric evaluation of the reduction of unrelated cord blood transplantation (UCBT)
      toxicity by using reduced intensity conditioning (RIC) in patients with acute myeloid
      leukaemia.UCBT related mortality and morbidity were limiting factors for the development of
      this procedure in adults. Non myeloablative conditioning regimen showed promising results and
      prospective evaluation has to be developed to confirm these retrospective data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individual meta-analysis is planned to compare geno-identical transplantation with
      myeloid-ablative or non myeloid-ablative conditioning with UCBT after RIC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>At 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficiency (overall survival, event free survival, relapse incidence, acute and chronic GVHD incidence, graft failure, venoocclusive disease, interstitial pneumonia, infections, comorbidity score, quality of life and medico-economic impact)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord blood transplantation after reduced intensity conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cord blood transplantation</intervention_name>
    <description>Umbilical cord blood transplantation after reduced intensity conditioning</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages : 4 to 65

          -  De novo or secondary AML requiring allogeneic transplant

          -  No donor (related or unrelated) compatible 10/10

          -  Complete remission excepted CR1 with t(8;21) or inv (16) or t (15;17)

          -  Smouldering AML without progression

          -  Signed assent of recipient

        Exclusion Criteria:

          -  If CR1: AML with with t(8;21) or inv (16) or t (15;17)

          -  Karnofsky &lt; 50% - Clearance of creatinin &lt; 40 ml/min

          -  Transaminases &gt; 8 N

          -  Previous autologous or allogeneic transplantation within 6 month prior to the study
             (except if tandem)

          -  total body irradiation contra-indicating 2 Gy TBI

          -  local irradiation contra-indicating 2 Gy TBI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard RIO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département d'Hématologie et d'Oncologie Médicale, Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord blood transplantation</keyword>
  <keyword>Conditioning regimen</keyword>
  <keyword>Acute myeloid leukaemia</keyword>
  <keyword>SORROR comorbidity index</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Innate immunity</keyword>
  <keyword>Immune reconstitution post transplant</keyword>
  <keyword>Umbilical Cord Blood Stem Cell Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

